Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Pim Sermsaksasithorn, Chanidapa Wongtada, Varin Chaaim, Yuda Chongpison & Pravit Asawanonda. (2022) On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study. Journal of Dermatological Treatment 33:7, pages 2963-2974.
Read now
Read now
Marco Galluzzo, Andrea Chiricozzi, Elisa Cinotti, Giovanna Brunasso, Maurizio Congedo, Maria Esposito, Chiara Franchi, Giovanna Malara, Alessandra Narcisi, Stefano Piaserico, Rossana Tiberio, Giuseppe Argenziano, Gabriella Fabbrocini & Aurora Parodi. (2022) Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations. Expert Opinion on Biological Therapy 22:3, pages 367-376.
Read now
Read now
Jonathan Barker, Giampiero Girolomoni, Alexander Egeberg, Joao Goncalves, Burkhard Pieper & Taegyun Kang. (2020) Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. Journal of Dermatological Treatment 31:8, pages 794-800.
Read now
Read now
Paolo Gisondi, Davide Geat, Andrea Conti, Paolo Dapavo, Stefano Piaserico, Clara De Simone, Luca Bianchi, Antonio Costanzo, Piergiorgio Malagoli, Giovanna Malara, Giuseppe Micali, Luigi Naldi, Annamaria Offidani, Annalisa Patrizi, F. Prignano, Aurora Parodi, Franco Rongioletti, Piergiacomo Calzavara-Pinton & Giampiero Girolomoni. (2020) TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. Expert Review of Clinical Immunology 16:6, pages 591-598.
Read now
Read now
Francesco Bellinato, Paolo Gisondi & Giampiero Girolomoni. (2020) A dermatologist perspective in the pharmacological treatment of patients with psoriasis and psoriatic arthritis. Expert Review of Clinical Pharmacology 13:5, pages 481-491.
Read now
Read now
Marco Galluzzo, Simone D’Adamio, Dionisio Silvaggio, Paolo Lombardo, Luca Bianchi & Marina Talamonti. (2020) In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opinion on Biological Therapy 20:2, pages 173-182.
Read now
Read now
Lynda Grine & Jo Lambert. (2016) Psoriasis: burning down the host. Journal of Dermatological Treatment 27:1, pages 1-1.
Read now
Read now
Articles from other publishers (36)
M. E. Jacobson, R. S. Seshadri, R. Morimoto, E. Grinich, C. Haag, K. Nguyen & E. L. Simpson. (2023)
Early intervention and disease modification in atopic
dermatitis—the
current state of the field and barriers to progress
. Journal of the European Academy of Dermatology and Venereology.
Crossref
Crossref
Thomas Bieber. (2023) Disease modification in inflammatory skin disorders: opportunities and challenges. Nature Reviews Drug Discovery 22:8, pages 662-680.
Crossref
Crossref
Jeong Hwa Lee & Mi-Young Lee. (2023) In Vitro and In Vivo Anti-Psoriasis Activity of Ficus carica Fruit Extracts via JAK-STAT Modulation. Life 13:8, pages 1671.
Crossref
Crossref
K. Schäkel, K. Reich, K. Asadullah, A. Pinter, D. Jullien, P. Weisenseel, C. Paul, M. Gomez, S. Wegner, Y. Personke, F. Kreimendahl, Y. Chen, J. Angsana, M. W. L. Leung & K. Eyerich. (2023)
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase
IIIb
randomized, double‐blind, parallel‐group,
GUIDE
study
. Journal of the European Academy of Dermatology and Venereology.
Crossref
Crossref
Francesco Bellinato, Paolo Gisondi, Guido Mioso, Elena Mason, Danny Straiotto, Stefano Piaserico & Giampiero Girolomoni. (2023) The transition from mild to moderate‐to‐severe chronic plaque psoriasis. Journal of the European Academy of Dermatology and Venereology.
Crossref
Crossref
Lars Iversen, Curdin Conrad, Liv Eidsmo, Antonio Costanzo, Joanna Narbutt, Andreas Pinter, Külli Kingo, Raquel Rivera Diaz, Frank Kolbinger, ManikPrabhu Nanna, Jennifer Annika Frueh & Piotr Jagiello. (2023)
Secukinumab demonstrates superiority over narrow‐band ultraviolet B phototherapy in new‐onset moderate to severe plaque psoriasis patients: Week 52 results from the
STEPIn
study
. Journal of the European Academy of Dermatology and Venereology 37:5, pages 1004-1016.
Crossref
Crossref
Clara Sophie Bramsen Andersen, Amanda Kvist-Hansen, Mie Siewertsen, Christian Enevold, Peter Riis Hansen, Diljit Kaur-Knudsen, Claus Zachariae, Claus Henrik Nielsen, Nikolai Loft & Lone Skov. (2023) Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis. International Journal of Molecular Sciences 24:7, pages 6111.
Crossref
Crossref
Mahira El Sayed, Ranya Lotfi, Dalia Hossam, Pola Onsy & Ahmed Elhawatky. (2023) Assessment of vascular patterns during the treatment of psoriatic patients using narrow‐band ultraviolet B phototherapy by the dermoscope. Photodermatology, Photoimmunology & Photomedicine 39:2, pages 100-106.
Crossref
Crossref
Yuxiong Jiang, Youdong Chen, Qian Yu & Yuling Shi. (2023) Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities. BioDrugs 37:1, pages 35-55.
Crossref
Crossref
Paulo Antônio Oldani Felix, Ana Luisa Sampaio, Bruno Leonardo Silva & Analia Luiza Porto Viana. (2022) Early intervention in psoriasis: Where do we go from here?. Frontiers in Medicine 9.
Crossref
Crossref
Maha Abo-Tabik, Rosa Parisi, Catharine Morgan, Sarah Willis, Christopher EM Griffiths & Darren M Ashcroft. (2022) Mapping opportunities for the earlier diagnosis of psoriasis in primary care settings in the UK: results from two matched case–control studies. British Journal of General Practice 72:724, pages e834-e841.
Crossref
Crossref
Francesco Cusano, Francesca Sampogna, Alexandra Maria Giovanna Brunasso Vernetti, Stefano Stisi, Gilda Sandri, Giovanna Malara, Luigi Naldi, Michele Pellegrino, Giovanni Luigi Tripepi, Umberto Di Luzio Paparatti, Concetto Paolo Agnusdei, Claudio Bonifati, Antonella Celano, Valeria Corazza, Federica D'Agostino, Rocco De Pasquale, Emilio Filippucci, Rosario Foti, Giovanna Galdo, Fabiana Gai, Giulia Ganzetti, Dario Graceffa, Mara Maccarone, Annamaria Mazzotta, Gennaro Melchionda, Francesca Molinaro, Franco Paoletti, Silvia Tonolo, Adriano Vercellone, Rosetta Vitetta, Cesare Massone & Gian Domenico Sebastiani. (2022) A consensus-based approach on the management of patients with both psoriasis and psoriatic arthritis in the dermatological and rheumatological settings in Italy: The ADOI PSO-Amore Project. Dermatology Reports 14:3.
Crossref
Crossref
Claire Reid, Charlotte Welsh, Holly Martin-Smith, Soney Dharmaprasad, Richard B. Warren, Lis Cordingley & Christopher E.M. Griffiths. (2022) A rapid access clinic for psoriasis: first experiences. British Journal of Dermatology 187:3, pages 426-428.
Crossref
Crossref
Ketty Peris, Anna Belloni Fortina, Luca Bianchi, Gabriella Fabbrocini, Paolo Gisondi, Anna Balato, Federico Bardazzi, Nicoletta Bernardini, Domenico Bonamonte, Maria Rita Bongiorno, Cinzia Buligan, Francesco Cusano, Maria Beatrice De Felici Del Giudice, May El Hachem, Maria Concetta Fargnoli, Giulio Gualdi, Claudio Guarneri, Katharina Hansel, Giovanna Malara, Carlo Mazzatenta, Giuseppe Micali, Alessandra Narcisi, Iria Neri, Teresa Oranges, Michele Panzone, Aurora Parodi, Lucia Restano, Oriana Simonetti, Marina Venturini & Vito Di Lernia. (2022) Update on the Management of Pediatric Psoriasis: An Italian Consensus. Dermatology and Therapy 12:8, pages 1753-1775.
Crossref
Crossref
L. S. Kruglova, E. A. Shatokhina, A. S. Polonskaya & A. Yu. Syryseva. (2022) Choice of frst drug of genetically engineered therapy: Benefts of guselcumab. Medical alphabet:8, pages 48-55.
Crossref
Crossref
Hyuk Soon Kim & Geunwoong Noh. (2022) Immunotherapy using Histobulin™ in psoriasis: A case report. Clinical Case Reports 10:5.
Crossref
Crossref
Kim Papp, Carle Paul, C. Elise Kleyn, Yu-Huei Huang, Tsen-Fang Tsai, Christopher Schuster, Celine El Baou, Agoston Toth, Elisabeth Riedl & Ulrich Mrowietz. (2022) Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis. Acta Dermato-Venereologica 102, pages adv00672.
Crossref
Crossref
Georgios Kokolakis, Kasper Vadstrup, Jes B. Hansen & Jose Manuel Carrascosa. (2022) Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis. Dermatology 238:4, pages 620-629.
Crossref
Crossref
Anna Campanati, Andrea Marani, Emanuela Martina, Federico Diotallevi, Giulia Radi & Annamaria Offidani. (2021) Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines 9:11, pages 1511.
Crossref
Crossref
K. Reich, J.B. Hansen, L. Puig, M.P. Konstantinou & R.B. Warren. (2021) Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE‐2 and AMAGINE‐3. Journal of the European Academy of Dermatology and Venereology 35:10, pages 2034-2044.
Crossref
Crossref
Kilian Eyerich, Peter Weisenseel, Andreas Pinter, Knut Schäkel, Khusru Asadullah, Sven Wegner, Ernesto J Muñoz-Elias, Holger Bartz, Friedmann J H Taut & Kristian Reich. (2021) IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open 11:9, pages e049822.
Crossref
Crossref
Krishna Yadav, Deependra Singh & Manju Rawat Singh. (2021) Novel archetype in psoriasis management bridging molecular dynamics in exploring novel therapies. European Journal of Pharmacology 907, pages 174254.
Crossref
Crossref
C.R.H. Hedin, E. Sonkoly, M. Eberhardson & M. Ståhle. (2021) Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach. Journal of Internal Medicine 290:2, pages 257-278.
Crossref
Crossref
N.J. Korman. (2019) Management of psoriasis as a systemic disease: what is the evidence?. British Journal of Dermatology 182:4, pages 840-848.
Crossref
Crossref
L. Grine, M. Brassinne, P.‐D. Ghislain, T. Hillary, J. Lambert, S. Segaert, F. Willaert & J. Lambert. (2020) A Belgian consensus on the definition of a treat‐to‐target outcome set in psoriasis management. Journal of the European Academy of Dermatology and Venereology.
Crossref
Crossref
Megan Breuer. (2019) Pathways to Silencing Psoriasis: Remission or Cure?. EMJ Dermatology, pages 2-8.
Crossref
Crossref
Yi-Wei Huang & Tsen-Fang Tsai. (2019) Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience. Dermatology and Therapy 9:3, pages 553-569.
Crossref
Crossref
L. Iversen, L. Eidsmo, J. Austad, M. Rie, A. Osmancevic, L. Skov, T. Talme, I. Bachmann, P. Kerkhof, M. Stahle, R. Banerjee, J. Oliver, A.E.R. Fasth & J. Frueh. (2018)
Secukinumab treatment in new‐onset psoriasis: aiming to understand the potential for disease modification – rationale and design of the randomized, multicenter
STEPI
n study
. Journal of the European Academy of Dermatology and Venereology 32:11, pages 1930-1939.
Crossref
Crossref
P. Gisondi, G. Altomare, F. Ayala, A. Conti, P. Dapavo, C. De Simone, C. Foti, L. Idolazzi, E. Lubrano, G. Malara, A. Marchesoni, I. Olivieri, A. Parodi, K. Peris, S. Piaserico, C. Salvarani, R. Scarpa & G. Girolomoni. (2018) Consensus on the management of patients with psoriatic arthritis in a dermatology setting. Journal of the European Academy of Dermatology and Venereology 32:4, pages 515-528.
Crossref
Crossref
Jane Grills. (2018) Interleukin-23 in Psoriasis: Integrating New Therapies in the Current Treatment Landscape. European Medical Journal, pages 22-29.
Crossref
Crossref
Blair Hesp. (2017) Linking Pathophysiology to Clinical Options in Psoriasis: New Insights into Interleukin-23. European Medical Journal, pages 52-58.
Crossref
Crossref
Tulin Ergun, Dilek Seckin Gencosmanoglu, Elif Karakoc‐Aydiner, Andac Salman, Burak Tekin, Emel Bulbul‐Baskan, Erkan Alpsoy, Aylin Cakıroglu & Nahide Onsun. (2016) Prevalence of obesity in paediatric psoriasis and its impact on disease severity and progression. Australasian Journal of Dermatology 58:4.
Crossref
Crossref
C.E.M. Griffiths. (2017) Systems medicine and psoriasis. British Journal of Dermatology 176:3, pages 560-562.
Crossref
Crossref
Paola Di Meglio & Frank O. Nestle. 2017. Clinical and Basic Immunodermatology. Clinical and Basic Immunodermatology
373
395
.
S Urbancek, R Sutka, Z Kmecova, J Salkovska, I Vano, T Pecova & J Rovensky. (2016) Screening of Patients with Psoriasis for Psoriatic Arthritis in the Slovak Republic. Acta Medica Martiniana 16:3, pages 32-42.
Crossref
Crossref
Aleksandra Batycka-Baran, Petra Besgen, Ronald Wolf, Jacek C. Szepietowski & Joerg C. Prinz. (2016) The effect of phototherapy on systemic inflammatory process in patients with plaque psoriasis. Journal of Photochemistry and Photobiology B: Biology 161, pages 396-401.
Crossref
Crossref